Major innovator brands see no price reductions despite cuts of up to 93 per cent for some cancer medicines; patient groups say PAP exclusions and data gaps have diluted relief
Domestic manufacturers want importers' margins included in a uniform trade margin framework for medical devices, with a pilot covering high-volume consumables such as IV sets
Drug regulators in Maharashtra, Karnataka and Uttar Pradesh are gathering data on price mark-ups, potentially strengthening the case for a review of trade margin rationalisation
The drug pricing regulator has directed manufacturers to regularly furnish production and sales data for scheduled formulations to strengthen monitoring of essential medicines
NPPA raises ceiling prices of key cancer drugs and select vaccines to address supply shortages and ensure continued availability of essential medicines
Drug pricing regulator permits marginal MRP increase for NLEM medicines in line with wholesale price index, offering relief to manufacturers facing higher costs
The NPPA has extended the knee implant price cap despite industry requests to remove or relax it, citing rising costs and innovation needs, as the regulator prioritises affordability for patients
The NPPA has extended the ceiling price for knee implants till November 2025 while considering industry pleas for removal, citing rising costs and supply chain issues
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments, citing steep price drops and growing generic availability
The NPPA has fixed retail prices for 84 drug formulations, including 36 combinations of off-patent diabetes drug empagliflozin, after a steep drop in prices
With the changes, manufacturers will be allowed to increase the maximum retail price (MRP) of scheduled formulations on the basis of WPI without needing any prior approval from the government
With this, manufacturers will be allowed to increase the maximum retail price (MRP) of scheduled formulations on the basis of WPI without needing any prior approval from the government in this regard
Under the AMRIT initiative, medicines for cancer, cardiovascular diseases, and surgical implants are available at up to 50 per cent discounts in selected hospital pharmacies
The regulatory body, which comes under the Department of Pharmaceuticals (DoP), took the decision to revise the prices of the formulations during the authority's 130th meeting on February 25
The National Pharmaceutical Pricing Authority directs pharma firms to revise the MRP of medicines following customs duty exemptions in Union Budget 2025, ensuring consumers benefit from lower prices
Parliamentary panel slams drug pricing regulator for hike on 11 drugs used for treating conditions such as asthma, glaucoma, thalassemia, tuberculosis, and mental health disorders
